Somatuline Depot (lanreotide) — Medica
Acromegaly
Initial criteria
- Patient has had an inadequate response to surgery and/or radiotherapy OR patient is not an appropriate candidate for surgery and/or radiotherapy OR patient is experiencing negative effects due to tumor size (e.g., optic nerve compression)
- Patient has (or had) a pre-treatment (baseline) insulin-like growth factor-1 (IGF-1) level above the upper limit of normal (ULN) based on age and gender for the reporting laboratory
- Medication is prescribed by or in consultation with an endocrinologist
Reauthorization criteria
- Prescriber continues to be an endocrinologist or in consultation with one
- Continued need for treatment as determined by clinical assessment
Approval duration
1 year